- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Bristol-Myers Squibb Company Ce(CELG-RI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CELG-RI
11/13/2026: CELG-RI (1-star) is currently NOT-A-BUY. Pass it for now.
Bristol-Myers Squibb is a major global biopharmaceutical company known for strong operating margins, cash generation, and a leading portfolio in oncology, immunology, and cardiovascular care. Its primary investment strengths include durable blockbusters like Eliquis and Opdivo, alongside a proven history of strategic pipeline expansion through acquisitions. The core investment thesis centers on scaling novel cell therapies to replace revenues lost to patent expirations. However, investors must weigh ongoing generic erosion, clinical trial risks, and pricing pressures. The stock suits value and dividend-oriented investors seeking defensive healthcare exposure, requiring close monitoring of pipeline readouts and patent litigation milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While pipeline assets offer growth, overall top-line expansion is tempered by patent expirations on legacy blockbusters. |
| Momentum investor | Mixed fit | Treat Momentum fit as conditional on a positive Upturn signal (Strong Buy / Buy); stock price trends depend heavily on clinical readouts and regulatory catalysts. |
| Value investor | Strong fit | The stock frequently trades at reasonable valuation multiples relative to its earnings power and cash generation. |
| Dividend investor | Strong fit | The company offers an attractive and stable dividend yield supported by durable pharmaceutical cash flows. |
| Low-risk investor | Strong fit while signal remains positive | Large-cap pharmaceutical stability and defensive characteristics provide a buffer against broader market volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Biopharmaceutical stocks experience localized swings around clinical trial readouts and regulatory decisions. |
| Valuation risk | Low | Modest valuation multiples limit severe downside re-pricing risk from earnings misses. |
| Competition risk (Pfizer & Merck competition) | Medium / high | Intense market rivalry in immuno-oncology and anticoagulants threatens long-term product margins. |
| Business quality | Strong | The company possesses an established global franchise, deep clinical expertise, and high-margin pharmaceutical assets. |
| Dividend income | Low | Payouts are well-covered by steady cash flows, offering reliable income return characteristics. |
| Execution risk | Medium / high | Successful clinical trial pipelines and commercialization of new cell therapies are critical to replacing lost revenues. |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 22.3K shares | Beta - | 52 Weeks Range 0.02 - 0.27 | Updated Date 12/06/2024 |
52 Weeks Range 0.02 - 0.27 | Updated Date 12/06/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Sector & Industry Intelligence
Sector intelligence is unavailable for this snapshot.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -51.11% | Avg. Invested days 2 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cardiovascular Portfolio | Includes global sales of Eliquis and related cardiovascular treatments. | Provides a steady bedrock of blockbuster prescription revenues. |
| Oncology & Hematology Portfolio | Encompasses flagship cancer drugs like Opdivo, Revlimid, and Pomalyst. | Drives high-margin specialized sales but faces long-term patent loss challenges. |
| Geography - United States & International | Commercial distribution across the U.S., Europe, and international markets. | The United States serves as the primary profit engine for commercial drug sales. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

